RENOVORX, INC. (RNXT) Spending and interest coverage
- R&D / revenue · 12 months: Value 284.87%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 76.97%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 284.87% | Research and development expense / revenue. Period ending 2026-06-30. $5.63M ÷ $1.98M × 100 ≈ 284.87% |
| Stock-based compensation / revenue · 12 months | 76.97% | Share-based compensation / revenue. Period ending 2026-06-30. $1.52M ÷ $1.98M × 100 ≈ 76.97% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 5.63M USD | Research and Development Expense |
| Revenue | 1.98M USD | |
| Stock-based compensation | 1.52M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -13.54M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.63M | $1.98M | $1.52M | $-13.54M | (m) | 284.87% | 76.97% | (m) | (m) |
| 2026-03-31 | $5.86M | $1.49M | $1.30M | $-12.87M | (m) | 393.22% | 87.04% | (m) | (m) |
| 2025-12-31 | $6.27M | $1.12M | $1.27M | $-12.51M | (m) | 558.24% | 112.82% | (m) | (m) |
| 2025-09-30 | $6.34M | (m) | $1.23M | $-11.62M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $6.29M | (m) | $1.14M | $-11.25M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $6.41M | (m) | $1.04M | $-11.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $6.03M | $43.00K | $1.17M | $-10.97M | (m) | 14011.63% | 2730.23% | (m) | (m) |
| 2024-09-30 | $5.22M | (m) | $1.14M | $-10.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $5.20M | (m) | $1.13M | $-10.27M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $5.59M | (m) | $1.14M | $-10.61M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $5.67M | (m) | $1.08M | $-11.40M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $5.67M | (m) | $1.02M | $-11.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $4.88M | (m) | $925.00K | $-10.97M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $4.35M | (m) | $837.00K | $-10.21M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $4.30M | (m) | $644.00K | $-9.95M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $4.63M | (m) | $606.00K | $-10.14M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $4.55M | (m) | $469.00K | $-9.37M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $3.69M | (m) | $307.00K | $-7.62M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $3.04M | (m) | $147.00K | $-5.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $2.39M | (m) | $33.00K | $-3.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |